Abingdon Health plc reported final results for the year ended 30 June 2026 on 13 October 2026, showing higher sales and a smaller loss. According to a summary of the announcement, total Revenue rose 32% to £11.3 million, with contract development revenue up 56% to £5.0 million. Loss before tax narrowed to £2.0 million from £3.5 million, and gross Margin improved to 47.1%. The company reported adjusted EBITDA profitability in the second half of the year, although a full-year EBITDA figure was not available. Readers should check the numbers against the original release.

Cash and equivalents increased to £2.9 million, helped by £3.2 million of Equity raised during the year. The company said it expects continued revenue growth and an improved EBITDA position in the 2027 financial year, but noted that short-term delays affected the first quarter of the new year.

What the company does

Abingdon Health works in diagnostics, offering contract development and Manufacturing services for tests, an activity that accounts for part of its revenue. It also has product partnerships. It is AIM-quoted and a constituent of the FTSE AIM All Share Index. The fuller Business description was not part of the summary reviewed.

US expansion

On 25 September 2026 the company announced the official opening of a manufacturing hub at its Facility in Madison, Wisconsin. The hub adds capacity and infrastructure for domestically produced diagnostic testing products, and local and state officials attended the ceremony. The company is building its end-to-end contract development and manufacturing services for the US medical technology market. Earlier in the year, on 14 and 21 April, Abingdon said its shares would begin trading on the OTCQB market in the United States, and on 27 May it announced a US tax Credit agreement.

Other recent news

A UKAS ISO/IEC 17025 accreditation was announced on 29 September 2026, and a Shareholder open day on 8 September. A trading update followed on 29 July, a notice of results on 7 October, and a presentation at the Mello2026 event on 29 May. Earlier items included an earn-out consideration and equity issue on 19 May, the launch of the LVOne Stroke Test by UpFront Diagnostics on 11 May, an update on the Partnership with 4TEEN4 Pharmaceuticals on 6 May and an EMI share option scheme on 15 April. No Dividend was reported in the material reviewed. The loss narrowing from £3.5 million to £2.0 million, alongside revenue growth, suggests Operating Leverage is starting to appear, though the company remains loss-making over the full year and relies on external Capital to fund its growth plans.

Sector and index context

Contract development and manufacturing for diagnostics benefits from outsourcing by smaller medical technology developers, but competition and regulatory demands are significant, and quality accreditation is a selling point. Growth businesses on AIM often rely on equity raises while approaching break-even, which is the pattern visible here. The FTSE AIM All Share Index includes a number of healthcare and diagnostics names, and no information on Abingdon's weighting or movement in the index was found.

Key risks

Customer timing, project delays like those cited for the first quarter, a modest cash balance relative to expansion plans, further dilution and regulatory exposure in both the United Kingdom and the United States are the main risks.

What to watch next

Watch for the first-half trading update, confirmation that the second-half EBITDA profitability can be sustained, utilisation of the new US hub and any further accreditation or customer wins.